July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
The potential of using different forms of topical human platelet lysate eye drops to treat ocular surface diseases
Author Affiliations & Notes
  • Lily Wei Chen
    Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan
  • Chin-Te Huang
    Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan
    Department of Ophthalmology, Taipei Tzu Chi General Hospital, Hua-Lian, Taiwan
  • Hsiao-Sang Chu
    Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan
  • Wei-Li Chen
    Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan
  • Footnotes
    Commercial Relationships   Lily Chen, None; Chin-Te Huang, None; Hsiao-Sang Chu, None; Wei-Li Chen, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3857. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lily Wei Chen, Chin-Te Huang, Hsiao-Sang Chu, Wei-Li Chen; The potential of using different forms of topical human platelet lysate eye drops to treat ocular surface diseases. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3857.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Human platelet lysate (HPL) contains epitheliotrophic factors and may promote corneal epithelial healing with similar efficacy as human peripheral serum (HPS). We tested the hypothesis that different forms of human platelet lysate eye drops could be used to treat ocular surface diseases.

Methods : Two commercialized liquid HPLs, UltraGRO TM and PLTMax, were converted to lyophilized powder and compared with liquid HPLs and HPS after redissolution. Human corneal epithelial cell line, human neuron cell line (PC-12) and cultivated rabbit conjunctival cells were incubated with the different blood derivatives and evaluated for migration, proliferation, differentiation and the expression of neuronal processes (in PC-12). New Zealand white rabbits were used to evaluate in vivo abilities of the blood derivatives as topical eye drops in the treatment of corneal epithelial defects and dry eye. In vivo confocal microscopy was used to evaluate corneal epithelial morphology.

Results : In vitro experiments on cell proliferation, migration, and differentiation demonstrated no significant difference among the blood derivatives in human corneal epithelial cell line and rabbit conjunctival cells (p>0.05). Tested blood derivatives produced similar in vivo corneal epithelial healing (p>0.05). In vivo confocal microscopy for the three treatment groups revealed similar pattern of cell morphology during the healing process of corneal epithelial defect and dry eye models (p>0.05). The neurotrophic ability, in terms of cell proliferation and the expression of neuronal processes, was not statistically different for redissolved powder HPLs, liquid HPLs and HPS (p>0.05).

Conclusions : Redissolved lyophilized powder form of HPL showed similar corneal epitheliotrophic and neurotrophic abilities as the liquid HPLs and HPS. Both liquid and redissolved lyophilized powder HPLs may be user-friendly options that can replace HPS in the treatment of ocular surface diseases.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×